Ex Vivo TIMP-3 Gene Therapy to Prevent Coronary Artery Bypass Graft Failure

Technology
In development
University
Scouted & summarized by Halo AI

This ex vivo gene therapy delivers the TIMP-3 gene to saphenous vein grafts during CABG surgery to prevent maladaptive remodeling and graft failure. By enhancing the vein's biological resilience to arterial pressure, the treatment aims to prolong graft patency, improve long-term patient health, and reduce the necessity for repeat revascularization procedures. The therapy is currently being evaluated in a first-in-human clinical trial.

Overview

Coronary artery bypass graft (CABG) surgery is a standard procedure for treating heart disease, yet many vein grafts fail over time due to maladaptive remodeling when exposed to arterial pressure. This technology introduces an innovative gene therapy approach to prevent such failures. By treating harvested saphenous veins with an adenoviral vector carrying the TIMP-3 (tissue inhibitor of metalloproteinases-3) gene ex vivo, the procedure effectively reprograms the vein tissue to withstand the high-pressure arterial environment. This proactive, localized treatment aims to reduce wall thickening and occlusion, potentially providing a durable, long-term solution that improves patient outcomes and reduces the need for secondary surgeries.

Technical specifications

The therapy utilizes an adenoviral vector, Ad5.CMVTO.TIMP-3, to deliver the TIMP-3 gene directly into the harvested vein graft.

  • Treatment is performed ex vivo during the surgical window, immediately following vein harvesting from the patient's leg.
  • The 30-minute incubation process allows for efficient gene delivery before the vessel is grafted into the heart.
  • By increasing local levels of the TIMP-3 protein, the therapy regulates tissue remodeling and inhibits the migration and proliferation of vascular smooth muscle cells that lead to neointimal hyperplasia and graft failure.
  • The procedure is designed for seamless integration into the standard cardiac surgical workflow, requiring no specialized external facilities.
Technology readiness level

The technology is currently at TRL 4 (in development/early clinical testing). It has successfully moved from pre-clinical research into the first-in-human PROTECT clinical trial, which commenced in late 2025 to evaluate safety and determine tolerable dosing. The therapy is being investigated through a randomized, placebo-controlled trial sponsored by NHS Greater Glasgow and Clyde in partnership with the University of Glasgow and other...

Generated Jun 28, 2026. Please verify key information.

About University of Glasgow

The University of Glasgow is a comprehensive, research‑intensive public university in Scotland’s largest city. Industry collaborates via the James Watt Nanofabrication Centre—an advanced university cleanroom—and hospital‑based facilities at the Queen Elizabeth University Hospital, including the Imaging Centre of Excellence with NHS Greater Glasgow & Clyde. The adjacent West of Scotland Science Park offers grow‑on space for companies and strong links back to campus. Research is supported by competitive funding from UK Research and Innovation councils and major charities such as Wellcome. Research & Innovation Services manages IP, licensing and spin‑out formation to speed commercialization.

Halo home
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.